You can buy or sell OptiNose and other stocks, options, ETFs, and crypto commission-free!
OptiNose, Inc. Common Stock, also called OptiNose, is a pharmaceutical company, which engages in the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. Read More Its products include the XHANCE and ONZETRA Xsail. The company was founded by Per Gisle Djupesland and Helena Kyttari Djupesland in May 2010 and is headquartered in Yardley, PA.
52 Week High
52 Week Low
Stock Price, News, & Analysis for OptiNose
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps. It also markets Onzetra Xsail (AVP-825) for...
Seeking AlphaMar 6
OptiNose, Inc. (OPTN) CEO Peter Miller on Q4 2018 Results - Earnings Call Transcript
OptiNose, Inc. (NASDAQ:OPTN) Q4 2018 Earnings Conference Call March 6, 2019 8:00 AM ET Company Participants Jonathan Neely - Vice President, Investor Relations and Business Operations Peter Miller - Chief Executive Officer Keith Goldan - Chief Financial Officer Tom Gibbs - Chief Commercial Officer Ramy Mahmoud - President and Chief Operating Officer Conference Call Participants Brandon Folkes - Cantor Fitzgerald David Amsellem - Piper Jaffray Gary Nachman - BMO Capital Markets Randall Stanicky - ...
Simply Wall StMar 1
Such Is Life: How OptiNose Shareholders Saw Their Shares Drop 58%
OptiNose, Inc. (NASDAQ:OPTN) shareholders should be happy to see the share price up 22% in the last month. But that doesn’t change the fact that the returns over the last year have been disappointing. Specifically, the stock price slipped by 58% in that time. It’s not that amazing to see a bounce after a drop like that. You could argue that the sell-off was too severe. Check out our latest analysis for OptiNose Given that OptiNose didn’t make a profit in the last twelve months, we’ll focus on revenue grow...
-$0.82 per share
-$0.64 per share